An Adaptive Design Study for the Assessment of the Safety, Tolerability and Pharmacokinetics of RYI-018 after Single Dosing in Healthy Volunteers and Repeat Dosing in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)
Phase 1
Recruiting
- Conditions
- on-Alcoholic Fatty Liver Disease
- Registration Number
- ACTRN12617000133336
- Lead Sponsor
- Bird Rock Bio Inc
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 84
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method